Years of difference in access to new cancer medicines for European patients


Patients living with cancer across Europe face highly unequal access to innovative cancer medicines, a new study of the Netherlands Cancer Institute and the European Fair Pricing Network found.

The researchers found wide variation in patient access to six innovative cancer medicines between countries, within countries, between different medicines, and between specialized and general hospitals, with Time to access ranging from -1 years to 7.1 years after EMA approval. The study was based on a survey among hospital pharmacists in 19 hospitals in six European countries.*)

Publication: ‘Differences in time to patient access to innovative cancer medicines in six European countries ’, International Journal of Cancer, October 2023.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.